Trials / Completed
CompletedNCT00063713
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 2 Study of VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (planned)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.
Detailed description
VELCADE is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. VELCADE is currently being studied in other types of cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VELCADE TM (bortezomib) for Injection |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2005-12-01
- First posted
- 2003-07-04
- Last updated
- 2008-02-11
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00063713. Inclusion in this directory is not an endorsement.